Yes, semaglutide can reduce visceral fat—the fat deep inside the abdomen around internal organs—as part of weight loss. Research supports that effect, but it does not mean the medicine selectively removes belly fat or that everyone loses the same amount. A smaller waist can be useful evidence of change; it cannot tell you exactly how much internal fat has disappeared.
The distinction matters when your scale, clothes, and body-composition report seem to tell different stories. Each measures something different. You can use those differences to understand progress without expecting one number to explain everything happening inside your abdomen.
Belly fat includes more than visceral fat
“Belly fat” is an everyday description of a location, not a single tissue compartment.
- Subcutaneous abdominal fat sits beneath the skin. Much of the soft tissue you can pinch belongs to this layer.
- Visceral fat, also called visceral adipose tissue or VAT, lies deeper, inside the abdominal cavity around organs. You cannot isolate it with a pinch test.
- Fat within the liver is a separate measurement. A liver-fat result is not interchangeable with a visceral-fat result, even though both concern metabolic health.
Excess visceral fat is associated with cardiometabolic risk, which is why researchers care about its reduction. Subcutaneous fat is not simply useless or universally harmless; the useful distinction is where tissue sits and what the measurement describes. Research comparing imaging methods separates visceral and subcutaneous compartments rather than treating all abdominal fat as one quantity.
Belly shape also reflects skin, posture, abdominal muscles, and digestive contents. A firm abdomen does not diagnose high visceral fat, and a soft abdomen does not rule it out. Photos can show a change in appearance; they cannot identify the fat compartment responsible.
What the semaglutide research actually measured
One useful source is the exploratory STEP 1 body-composition substudy, published as a conference abstract. It included 140 adults with overweight or obesity, without diabetes; 95 received once-weekly injected semaglutide 2.4 mg and 45 received placebo, alongside lifestyle intervention. Substudy eligibility required BMI at or below 40.
DXA, also written DEXA, assessed body composition at screening and week 68. The semaglutide group had these reported changes from baseline:
| Measurement | Change at week 68 |
|---|---|
| Body weight | −15.0% |
| Total fat mass | −19.3% |
| Regional visceral-fat mass | −27.4% |
Each percentage uses that measurement's own starting amount. The visceral-fat result does not mean 27.4% of body weight disappeared or that body-fat percentage fell by 27.4 points. Regional visceral-fat proportion fell by 2.0 percentage points, a different calculation.
This small, exploratory analysis used scanner-dependent regions rather than whole-abdomen MRI. It supports visceral-fat reduction during treatment, but cannot establish when it began, predict an individual's result, or transfer the percentages to other doses, formulations, or populations.
Does that mean semaglutide targets belly fat first?
The larger proportional decline in regional visceral fat is encouraging. It does not establish an order in which fat leaves the body. Measuring two endpoints cannot reveal whether internal fat changed before the layer under the skin.
Semaglutide acts on GLP-1 receptors and reduces calorie intake through effects on appetite, according to the U.S. Wegovy prescribing information, sections 12.1–12.2. That helps explain overall weight loss. The substudy does not isolate a special fat-burning effect independent of weight loss.
You cannot choose a patch of fat for the medicine to remove. Nor does the evidence promise a flat stomach: visceral fat can decrease while subcutaneous fat or loose skin still affects how the abdomen looks. An unchanged appearance does not prove treatment has failed, but it also does not prove hidden visceral-fat loss. The claim needs the appropriate measurement.
What your waist, scale, DXA, or MRI can establish
| Measurement | Useful information | Limit when asking about visceral fat |
|---|---|---|
| Scale weight | Change in total body mass | Cannot separate fat compartments, lean tissue, water, or digestive contents |
| Waist circumference | Abdominal size and a practical signal used in health-risk assessment | Cannot separate visceral from subcutaneous fat or convert inches lost into a visceral-fat percentage |
| Smart-scale “visceral fat” score | A device-generated estimate based on impedance and its prediction model | Does not image internal tissue; a score is not a directly measured quantity of visceral fat |
| DXA body-composition scan | Estimates total and regional composition; suitable software can estimate VAT | Needs a specific VAT analysis; total body-fat percentage or “android fat” alone is not isolated visceral fat |
| MRI or CT with fat analysis | Can distinguish visceral from subcutaneous tissue in the imaged region | Result depends on coverage and analysis; one slice, a regional area, and whole-abdomen volume are different measures |
The imaging comparison study found that DXA-derived VAT tracked MRI volume well across its study population. This does not make the methods interchangeable for every person. In particular, the study's impedance comparison used general fat estimates, not a dedicated visceral-fat output, so it cannot validate your scale's score.
MRI does not use ionizing radiation; CT does. Greater anatomical detail alone is not a reason to arrange repeated scans. Before paying for a test, ask what decision its result would change and whether the proposed scan actually includes the analysis you want.
Read a score as a score
If a home scale's visceral-fat rating changes from 12 to 10, you cannot conclude that you lost two pounds of visceral fat—or calculate a clinical fat-loss percentage from that change. The units, algorithm, and validation matter. Ratings from different brands may not even describe the same scale.
A falling estimate may be consistent with an improving overall pattern. It is still an estimate, not an independent view inside the abdomen. A sudden change in that number is not a reason to change a prescription.
Read a waist change as a change in size
The NIDDK explains why abdominal fat distribution adds useful health context beyond BMI. That makes waist size worth discussing, while leaving an important limit: a tape does not identify which tissue changed.
For example, a smaller waist with stable weight establishes a size change under comparable measuring conditions. It does not establish that muscle replaced visceral fat. If you want a repeatable measurement method, use the body-measurements guide; the interpretation remains separate from the technique.
Which evidence is useful for your next decision?
Start with the question you need answered.
“Is my overall treatment helping?” Weight and waist trends can contribute, alongside the treatment goal, tolerability, and relevant clinical measures. Blood pressure, glucose or HbA1c, and lipids concern health outcomes and risk; none tells you an exact amount of visceral fat. An improvement in glucose alone cannot prove internal fat loss because semaglutide also affects glucose regulation directly.
“Did a particular fat compartment change?” Ask whether a body-composition report actually reports VAT, which region it covers, and whether repeat results use comparable equipment and analysis. Comparing a home rating with an MRI volume cannot establish a rate of change.
“Am I losing muscle?” Visceral-fat measurements do not answer that question. Even a DXA lean-mass result is broader than skeletal muscle; the GLP-1 muscle-loss guide explains how composition, strength, and function fit together.
You do not need an exact visceral-fat number to have a useful treatment review. Bring the evidence you have, label it accurately, and ask what it changes about the plan. Semaglutide can reduce internal fat; the most useful reading is the one that answers your actual question without claiming more than it measured.

About the author
Maya Lee
Glowise Senior GLP-1 Content Editor
Maya Lee is a Glowise Health Content Editor. Her guides turn product records, authoritative sources, and everyday organization questions into clear, practical GLP-1 information.
She helps readers ask better questions and keep the details relevant to a care conversation together.
See more Glowise on Google
Add Glowise as a preferred source to find our GLP-1 guides more easily in Google Search.



